Literature DB >> 8318058

Reduction of Lp(a) plasma levels by bezafibrate.

F M Maggi, G M Biasi, A L Catapano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8318058     DOI： 10.1016/0021-9150(93)90075-6

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  5 in total

Review 1.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 2.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

3.  High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.

Authors:  K Saku; B Zhang; S Jimi; H Bai; K Hirata; N Sasaki; R Liu; K Arakawa
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Gemfibrozil and Mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol--pilot study.

Authors:  G Simoni; A Gianotti; A Ardia; A Baiardi; D Civalleri
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

Review 5.  Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach.

Authors:  Maria Francesca Greco; Cesare R Sirtori; Alberto Corsini; Marat Ezhov; Tiziana Sampietro; Massimiliano Ruscica
Journal:  J Clin Med       Date:  2020-07-03       Impact factor: 4.964
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.